Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals ($CRNX) announced that the Compensation Committee granted non-qualified stock option awards to fivenew non-executive employees

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer


Crinetics ($CRNX) today announced the appointment of James Hassard as chief commercial officer. Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies.

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan


Crinetics Pharmaceuticals ($CRNX) and Sanwa Kagaku Kenkyusho Co., Ltd. have entered into a strategic partnership to develop and commercialize paltusotine in Japan.

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference


Crinetics Pharmaceuticals ($CRNX) will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference on February 16 at 1:00pm ET

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals ($CRNX) announced that the Compensation Committee granted non-qualified stock option awards to seven new non-executive employees